Skip to main navigation Skip to search Skip to main content

ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant M. abscessus in caseum surrogate

  • Hackensack Meridian Health
  • University of Minnesota Twin Cities

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Necrotic lesions and cavities filled with caseum are a hallmark of mycobacterial pulmonary disease. Bronchocavitary Mycobacterium abscessus disease is associated with poor treatment outcomes. In caseum surrogate, M. abscessus entered an extended stationary phase showing tolerance to killing by most current antibiotics, suggesting that caseum persisters contribute to the poor performance of available treatments. Novel ADP-ribosylation-resistant rifabutin analogs exhibited bactericidal activity against these M. abscessus persisters at concentrations achievable by rifamycins in caseum.

Original languageEnglish
JournalAntimicrobial Agents and Chemotherapy
Volume67
Issue number9
DOIs
StatePublished - Sep 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • ADP-ribosylase
  • NTM
  • caseum
  • drug tolerance
  • non-tuberculous mycobacteria
  • persistence
  • rifamycins

Fingerprint

Dive into the research topics of 'ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant M. abscessus in caseum surrogate'. Together they form a unique fingerprint.

Cite this